Proactive Investors - Run By Investors For Investors

ANGLE's parsortix gets favourable peer review for use in therapy selection

"The incorporation of Parsortix in protocols for therapy selection has the potential to meet a key need in personalised medicine.
picture of blood sample
The University Medical Centre Hamburg-Eppendorf (UKE) published new research
ANGLE PLC’s (LON:AGL OTCQX:ANPCY) cancer cell collection technology has received another encouraging peer review in a leading scientific journal.
 
The University Medical Centre Hamburg-Eppendorf (UKE) published new research detailing the use of ANGLE's Parsortix system in the Clinical Chemistry journal.
 
ANGLE's chief executive, Andrew Newland, said: "This fourth peer-reviewed publication in a key scientific journal adds to the growing body of published evidence of 
Parsortix's superior performance as a liquid biopsy.  
 
"The incorporation of Parsortix in protocols for therapy selection has the potential to meet a key need in personalised medicine. 
 
“By facilitating the determination of which drugs will benefit individual patients and which will have little clinical benefit yet cause significant side effects, such protocols will also help reduce the burden on expensive healthcare resources."
 
Klaus Pantel, chairman, Department of Tumour Biology at UKE's Centre of Experimental Medicine, added: "We are excited about the new workflows utilising Parsortix to study multi marker profiles of single CTCs by low cost qPCR approaches.  
 
“The high expression levels of chemokines achieved with Parsortix offers the potential for its use in therapy selection for patients and we will be progressing further studies to determine specific applications."
View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
test tubes
May 02 2019
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use